Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 3 2Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1GIST 1

Interventions

Methotrexate 48Cyclophosphamide 47Vincristine 39Cytarabine 36Dexamethasone 33Mercaptopurine 32pegaspargase 30Doxorubicin 29Daunorubicin 26Etoposide 24Asparaginase 23Prednisone 22Radiotherapy 18Thioguanine 15Leucovorin 14Calcium Dobesilate 14merphos 12Prednisolone 12blinatumomab 11Hydrocortisone 10Whole-Body Irradiation 9dexamethasone acetate 8azathiopurine 8Methylprednisolone 8Ifosfamide 8Filgrastim 8Cyclosporine 8fludarabine 7dexamethasone 21-phosphate 7auricularum 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × olverembatinib × Clear all
NCT06051409 2026-04-30

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

Ascentage Pharma Group Inc.

Phase 3 Recruiting
350 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 3 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡